Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologiesRA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outl ...

RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-su ...

Core Viewpoint - Inspira Technologies is positioning itself to enter the multi-billion dollar liquid biopsy diagnostics market through a proposed acquisition and a strategic equity investment of $15 million, while ensuring protections for existing shareholders [1][2]. Equity Investment - The proposed transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's potential [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business, allowing Inspira to enter the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical studies, indicating its potential to provide valuable diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with a projected global liquid biopsy market size of approximately $58 billion over the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing regulatory precedents [7]. - An existing reimbursement code is already in place for the intended clinical use, facilitating a clear path to reimbursement upon regulatory clearance [8]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing technologies for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9]. - Existing shareholders are expected to receive contingent value rights, ensuring that future realizations of value from respiratory technology assets are allocated exclusively to them [9]. Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing IP portfolio [10].

Core Viewpoint - Inspira Technologies has announced a proposed two-part transaction involving the acquisition of a liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment, aimed at expanding into the high-growth diagnostics market [1][2]. Equity Investment - The transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's value [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing respiratory and blood monitoring technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business through an all-share transaction, allowing entry into the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical validation studies, indicating its potential to provide meaningful diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with applicability across other oncology indications, and the global liquid biopsy market is projected to reach approximately $58 billion in the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing reimbursement codes for intended clinical use [7]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing respiratory and blood-monitoring platforms for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9].

RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal cycle, in alignment with immediate regulatory sequencing and phased deployment milestones.The Com ...

Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal c ...

As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRA TECHNOLOGIES OXY B.H.N.LTD. (Exact name of registrant as specified in its charter) State of Israel 3841 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Nu ...

Core Insights - Several small-cap biotech and healthcare companies experienced notable gains in after-hours trading, driven by recent corporate updates and clinical milestones Company Updates - Inspira Technologies Oxy B.H.N. Ltd. (IINN) rose 5.88% to $1.08 following a recent definitive agreement for a registered direct offering of its ordinary shares and a Standby Equity Purchase Agreement with YA II PN, Ltd. [2] - Galectin Therapeutics Inc. (GALT) increased by 1.79% to close at $6.27, despite no new corporate developments reported [3] - MediciNova, Inc. (MNOV) advanced 4.83% to $1.52 after successfully completing patient enrollment in its Phase 2 OXTOX study, evaluating MN-166 for chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [4] - Marker Therapeutics, Inc. (MRKR) gained 5.56% to $1.33 without any new company-specific announcements [5] - Sharps Technology, Inc. (STSS) climbed nearly 4% to $2.09, also without fresh updates [6] - DiaMedica Therapeutics Inc. (DMAC) rose 2.89% to $8.55 after a productive pre-IND meeting with the FDA regarding its planned study of DM199 in preeclampsia [6] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) edged higher by 1.36% to $8.21, following the completion of its Phase 1a study of CRB-913 and initiation of the Phase 1b CANYON-1 trial [7] - ProMIS Neurosciences, Inc. (PMN) added 0.83% to $8.49, recovering slightly after a decline earlier in the day, with the completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for Alzheimer's disease [8]

Core Viewpoint - Inspira Technologies has announced a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement (SEPA) to enhance its financial flexibility and support its strategic initiatives [1][4][7]. Group 1: Registered Direct Offering - The company will issue and sell 1,565,217 ordinary shares at a price of $1.15 per share, generating gross proceeds of approximately $1.8 million [2][9]. - The offering is expected to close on or about December 16, 2025, pending customary closing conditions [2]. Group 2: Standby Equity Purchase Agreement (SEPA) - The SEPA allows the company to sell up to $25 million of its ordinary shares over a 36-month period at its discretion, without any minimum purchase requirements [4][9]. - The company is not obligated to utilize this facility, providing it with opportunistic capital raising options as needed [4][9]. Group 3: Use of Proceeds - The net proceeds from the registered direct offering and any future proceeds from the SEPA will be used for working capital and general corporate purposes, specifically to support the company's strategic roadmap and planned operations [6][9]. Group 4: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing intellectual property portfolio [8][10].

RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with YA II PN, Ltd. ("YA") for a registered direct offering of its ordinary shares, and has also entered into a Standby Equity Purchase Agreement ("SEPA") with YA providing additional equity financing flexibility.In ...